Please ensure Javascript is enabled for purposes of website accessibility

Why Celator Pharmaceuticals Shares Shot 11.9% Higher Today

By Todd Campbell - May 11, 2016 at 5:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company plans to file Vyxeos for FDA approval by the end of the third quarter.

Image source: Celator Pharmaceuticals,

What: After reporting first-quarter financials showing it's on firmer financial footing and reiterating plans to file for FDA approval of Vyxeos later this year, shares of Celator Pharmaceuticals  (NASDAQ: CPXX) jumped by 11.9% today.

So what: The clinical-stage drugmaker recently reported surprisingly positive phase 3 findings for its acute myeloid leukemia drug Vyxeos.

Vyxeos, a reformulation of two commonly used chemotherapy drugs in this indication, statistically improved overall survival by 3.61 days versus the standard of care while also delivering safety that was similar to the control arm of this study.

On Tuesday, management reaffirmed plans to present the FDA with data from this trial in hopes of securing a regulatory OK next year. The company believes it can complete its application for FDA approval by the end of the third quarter, and if so, then a decision could come from the agency by the middle of 2017.

Management also reported yesterday that money it raised via a stock offering in March provides it with enough financial firepower to last it into 2018.

Now what: Celator Pharmaceuticals exited March with $67.5 million in cash on the books, and since its operating expenses totaled only about $5 million last quarter, it would seem the company's on firm financial ground ahead of a potential launch of Vyxeos next year.

Although Vyxeos' efficacy and safety appear solid enough to secure a FDA green light, there's always the chance that regulators will reject Vyxeos. So there's still some risk associated with owning Celator Pharmaceuticals' stock. That said, this company has a good shot of becoming the standard of care in a market that could be valued at $900 million annually, and given that opportunity, this is one stock that risk-tolerant investors might want to consider buying.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.